It is a chronic inflammatory disease that can affect the entire body, not just the skin. It is estimated that there are 400,000 to 500,000 patients in the country.

What is 'PASI' in psoriasis treatment?

It is a scoring system used to quantify the severity of psoriasis. PASI90/100 refers to a 90%/100% improvement in symptoms.

What is the main role of biosimilars (follow-on biologics)?

They have equivalent quality, safety, and efficacy to the original biologic medicines, and contribute to reducing patient burden, optimizing healthcare costs, and sustaining the universal health insurance system.

How is the switch from an original biologic medicine to a biosimilar performed?

It is recommended to be conducted with the agreement of the attending physician, based on scientific evidence both domestically and internationally, while considering safety.

Where can this dialogue be viewed?

It is published on the official website of the Japan Biosimilars Council, and the PDF version can also be downloaded.

AI News NQ Analysis

Role and Expectations of Biosimilars in Psoriasis Treatment (Dialogue: Dr. Akiharu Morita, Nagoya City University)

NQ Score 82/100

N1 Content Completeness 9

AI Summary (NQ-processed)

The Japan Biosimilar Association has released an expert dialogue titled 'Role and Expectations of Biosimilars in Psoriasis Treatment' featuring Dr. Akiharu Morita of Nagoya City University.

AI Analysis

Frequently Asked Questions

Q: What is psoriasis?: A: It is a chronic inflammatory disease that can affect the entire body, not just the skin. It is estimated that there are 400,000 to 500,000 patients in the country.
Q: What is 'PASI' in psoriasis treatment?: A: It is a scoring system used to quantify the severity of psoriasis. PASI90/100 refers to a 90%/100% improvement in symptoms.
Q: What is the main role of biosimilars (follow-on biologics)?: A: They have equivalent quality, safety, and efficacy to the original biologic medicines, and contribute to reducing patient burden, optimizing healthcare costs, and sustaining the universal health insurance system.
Q: How is the switch from an original biologic medicine to a biosimilar performed?: A: It is recommended to be conducted with the agreement of the attending physician, based on scientific evidence both domestically and internationally, while considering safety.
Q: Where can this dialogue be viewed?: A: It is published on the official website of the Japan Biosimilars Council, and the PDF version can also be downloaded.